Literature DB >> 21443082

Preoperative portal vein embolization for hilar cholangiocarcinoma--a comparative study.

Bin Yi1, Ai-Min Xu, Eric C H Lai, Zeng-Qiang Qu, Qing-Bao Cheng, Chen Liu, Xiang-Ji Luo, Yong Yu, Ying-He Qiu, Xiao-Yan Wang, Hong-Yan Cheng, Bai-He Zhang, Feng Shen, Wan Yee Lau, Meng-Chao Wu, Xiao-Qing Jiang.   

Abstract

BACKGROUND/AIMS: Preoperative portal vein embolization (PVE) allows potentially curative hepatic resection to be carried out in patients with hepatobiliary malignancies who are otherwise not candidates for resection because of the small size of the future liver remnant (FLR). However, there have only been a few reports on PVE before hepatectomy for hilar cholangiocarcinoma due to the small number of patients who can be treated with radical surgery.
METHODOLOGY: Between January 2007 and March 2009, 49 consecutive patients with hilar cholangiocarcinoma who were planned to have hemi-hepatectomy/extended hemi-hepatectomy plus caudate lobe resection in our tertiary referral center were studied. The change in size of the FLR and the operative outcomes were compared between patients with or without PVE.
RESULTS: All patients had liver dysfunction as a result of biliary obstruction due to hilar cholangiocarcinoma although they had all received percutaneous transhepatic biliary drainage. PVE was used in 16 patients with an estimated FLR of <50%, while no PVE was carried out in 33 patients with an estimated FLR of >50%. Complications after PVE occurred in 3 patients (18.8%), which included bile leakage (n=1) and coil displacement (n=2). No complication precluded liver resection. The FLR to total liver volume (TLV) ratio at presentation was significantly smaller in patients who underwent PVE than those who did not undergo PVE (40.3 +/- 7.4% vs. 56.6 +/- 5.0%; p < 0.001). After PVE, the FLR to TLV ratio increased significantly (40.3 +/- 7.4% vs. 43.1 +/- 7.0%; p < 0.001) at a mean time of 14.2 +/- 3.5 days. The mean +/- S.D. increase in FLR was 4.6 +/- 3.0 cm3/day. At surgery, the FLR volume was still significantly smaller in the PVE group than the non-PVE (802 +/- 216 cm3 vs. 979 +/- 202 cm3; p = 0.007). In the PVE group, insufficient hypertrophy of the FRL prevented one patient from having surgery, while local tumor progression and peritoneal dissemination precluded hepatectomy in 2 more patients. Finally, 13 patients (81.3%) underwent radical surgery. The PVE group had similar complication and mortality rates compared with the non-PVE group (complication rate, 69.2% vs. 63.6%; mortality rate, 0.0% vs. 9.1%). The 1- and 2-year overall survivals for the PVE group (with intent-to-treat analysis), PVE group (radical surgery only) and the non-PVE group were 57.3% and 43.0%; 71.3% and 53.5%; 70.4% and 54.4%, respectively. There was no significant difference in the survival outcomes.
CONCLUSIONS: The results suggested that PVE is a safe and efficacious procedure in inducing adequate hypertrophy of the FLR before major hepatic resection for hilar cholangiocarcinoma with obstructive jaundice which had been relieved by percutaneous transhepatic biliary drainage.

Entities:  

Mesh:

Year:  2010        PMID: 21443082

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  6 in total

Review 1.  Epidemiology and surgical management of intrahepatic cholangiocarcinoma.

Authors:  Han Zhang; Feng Shen; Jun Han; Yi-Nan Shen; Guo-Qiang Xie; Meng-Chao Wu; Tian Yang
Journal:  Hepat Oncol       Date:  2015-11-30

Review 2.  Percutaneous vs. endoscopic pre-operative biliary drainage in hilar cholangiocarcinoma - a systematic review and meta-analysis.

Authors:  Ahmer Hameed; Tony Pang; Judy Chiou; Henry Pleass; Vincent Lam; Michael Hollands; Emma Johnston; Arthur Richardson; Lawrence Yuen
Journal:  HPB (Oxford)       Date:  2016-04-04       Impact factor: 3.647

3.  Hepatic Artery Resection for Bismuth Type III and IV Hilar Cholangiocarcinoma: Is Reconstruction Always Required?

Authors:  Hai-Jie Hu; Yan-Wen Jin; Rong-Xing Zhou; Anuj Shrestha; Wen-Jie Ma; Qin Yang; Jun-Ke Wang; Fei Liu; Nan-Sheng Cheng; Fu-Yu Li
Journal:  J Gastrointest Surg       Date:  2018-03-06       Impact factor: 3.452

Review 4.  Multimodal treatment strategies for advanced hilar cholangiocarcinoma.

Authors:  Matthew J Weiss; David Cosgrove; Joseph M Herman; Neda Rastegar; Ihab Kamel; Timothy M Pawlik
Journal:  Langenbecks Arch Surg       Date:  2014-06-25       Impact factor: 3.445

5.  Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China.

Authors:  Hai-Jie Hu; Hui Mao; Anuj Shrestha; Yong-Qiong Tan; Wen-Jie Ma; Qin Yang; Jun-Ke Wang; Nan-Sheng Cheng; Fu-Yu Li
Journal:  World J Gastroenterol       Date:  2016-02-28       Impact factor: 5.742

6.  A New Surgical Procedure "Dumbbell-Form Resection" for Selected Hilar Cholangiocarcinomas With Severe Jaundice: Comparison With Hemihepatectomy.

Authors:  Shuguang Wang; Feng Tian; Xin Zhao; Dajiang Li; Yu He; Zhihua Li; Jian Chen
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.